Mural Oncology Stock Forum

$Mural Oncology (MURA.US)$ Is a recovery possible?

$Mural Oncology (MURA.US)$ filed chapter 11?

$Mural Oncology (MURA.US)$ Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
3 MINUTES AGO, 6:30 AM EDT
VIA GLOBENEWSWIRE
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis
Continued demonstration of favorable tolerability profile generally consistent with previously reported d...

$Mural Oncology (MURA.US)$
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Thursday, 9th January at 4:00 pm
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma
Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma expected in 1H 2025 for monotherapy, with patient enrollment...

$Mural Oncology (MURA.US)$
Mural Oncology's Cancer Drug Shows 33% Response Rate in Melanoma Trial Data | MURA Stock News

$Mural Oncology (MURA.US)$
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology has published promising clinical data from its completed ARTISTRY-1 phase 1/2 trial of nemvaleukin, showing positive antitumor activity in both monotherapy and combination therapy with pembrolizumab.
The trial, involving 286 patient...

$Mural Oncology (MURA.US)$
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Mural Oncology presented clinical and preclinical data at the 39th SITC Annual Meeting. The ARTISTRY-3 trial showed that less frequent IV dosing of nemvaleukin demonstrated tumor site-specific immune activation in ovarian cancer and mucosal melanoma patients. Preclinical data from IL-18 variants showed durable immune ...

$Mural Oncology (MURA.US)$
Mural Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.90%)

$Mural Oncology (MURA.US)$
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...

$Mural Oncology (MURA.US)$
NEWS
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting